Cargando…

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome

INTRODUCTION: Despite comparatively favourable prognosis in polycythemia vera (PV) patients (pts), the overall survival is shorter compared to the age-matched general population. The aim of the study was to evaluate the impact of chosen laboratory and genetic factors on the individual disease outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanduła, Zuzanna, Janowski, Michał, Więckowska, Barbara, Paczkowska, Edyta, Lewandowski, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349754/
https://www.ncbi.nlm.nih.gov/pubmed/36242602
http://dx.doi.org/10.1007/s00432-022-04327-0
_version_ 1785073987952312320
author Kanduła, Zuzanna
Janowski, Michał
Więckowska, Barbara
Paczkowska, Edyta
Lewandowski, Krzysztof
author_facet Kanduła, Zuzanna
Janowski, Michał
Więckowska, Barbara
Paczkowska, Edyta
Lewandowski, Krzysztof
author_sort Kanduła, Zuzanna
collection PubMed
description INTRODUCTION: Despite comparatively favourable prognosis in polycythemia vera (PV) patients (pts), the overall survival is shorter compared to the age-matched general population. The aim of the study was to evaluate the impact of chosen laboratory and genetic factors on the individual disease outcome, i.e. risk of thrombosis, myelofibrosis/blastic transformation and death. MATERIALS AND METHODS: The study group consisted of 151 pts and 57 healthy donors (HD). RESULTS: JAK2V617F mutation was found in 96.7% (146/151) of the studied pts. JAK2 exon 12 mutations were identified in 2 individuals. The coexistence of JAK2V617F and JAK2 exon 12 mutation was confirmed in 2 other pts. In one case, neither JAK2V617F nor JAK2 exon 12 mutation was found. The presence of ten different non-driver mutations (ASXL1, SRSF2, U2AF1, IDH2) in eight of the analyzed pts (5.3%) was confirmed. The overall frequency of thrombotic events (TE) in the studied PV group was 23.8% (36/151). In patients with TE, median platelet count was lower than in pts without TE. Thrombotic risk did not depend on JAK2 rs12343867, TERT rs2736100, OBFC1 rs9420907 SNV, however, we found a novel strong tendency towards statistical significance between the CC genotype miR-146a rs2431697 and thrombosis. The disease progression to fibrotic phase was confirmed in 9% of the pts. Fibrotic transformation in PV pts was affected mainly by JAK2V617F variant allele frequency (VAF) and the presence of coexisting non-driver variants. The high JAK2V617F VAF and elevated white blood cell (WBC) count at the time of diagnosis were associated with an increased risk of death. CONCLUSION: Therefore, in our opinion, complex, laboratory and genetic PV pts evaluation at the time of diagnosis should be incorporated into a new prognostic scoring system to more precisely define the PV prognosis and to optimize the therapeutic decision-making process. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04327-0.
format Online
Article
Text
id pubmed-10349754
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103497542023-07-17 JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome Kanduła, Zuzanna Janowski, Michał Więckowska, Barbara Paczkowska, Edyta Lewandowski, Krzysztof J Cancer Res Clin Oncol Research INTRODUCTION: Despite comparatively favourable prognosis in polycythemia vera (PV) patients (pts), the overall survival is shorter compared to the age-matched general population. The aim of the study was to evaluate the impact of chosen laboratory and genetic factors on the individual disease outcome, i.e. risk of thrombosis, myelofibrosis/blastic transformation and death. MATERIALS AND METHODS: The study group consisted of 151 pts and 57 healthy donors (HD). RESULTS: JAK2V617F mutation was found in 96.7% (146/151) of the studied pts. JAK2 exon 12 mutations were identified in 2 individuals. The coexistence of JAK2V617F and JAK2 exon 12 mutation was confirmed in 2 other pts. In one case, neither JAK2V617F nor JAK2 exon 12 mutation was found. The presence of ten different non-driver mutations (ASXL1, SRSF2, U2AF1, IDH2) in eight of the analyzed pts (5.3%) was confirmed. The overall frequency of thrombotic events (TE) in the studied PV group was 23.8% (36/151). In patients with TE, median platelet count was lower than in pts without TE. Thrombotic risk did not depend on JAK2 rs12343867, TERT rs2736100, OBFC1 rs9420907 SNV, however, we found a novel strong tendency towards statistical significance between the CC genotype miR-146a rs2431697 and thrombosis. The disease progression to fibrotic phase was confirmed in 9% of the pts. Fibrotic transformation in PV pts was affected mainly by JAK2V617F variant allele frequency (VAF) and the presence of coexisting non-driver variants. The high JAK2V617F VAF and elevated white blood cell (WBC) count at the time of diagnosis were associated with an increased risk of death. CONCLUSION: Therefore, in our opinion, complex, laboratory and genetic PV pts evaluation at the time of diagnosis should be incorporated into a new prognostic scoring system to more precisely define the PV prognosis and to optimize the therapeutic decision-making process. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04327-0. Springer Berlin Heidelberg 2022-10-15 2023 /pmc/articles/PMC10349754/ /pubmed/36242602 http://dx.doi.org/10.1007/s00432-022-04327-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Kanduła, Zuzanna
Janowski, Michał
Więckowska, Barbara
Paczkowska, Edyta
Lewandowski, Krzysztof
JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
title JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
title_full JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
title_fullStr JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
title_full_unstemmed JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
title_short JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
title_sort jak2v617f variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349754/
https://www.ncbi.nlm.nih.gov/pubmed/36242602
http://dx.doi.org/10.1007/s00432-022-04327-0
work_keys_str_mv AT kandułazuzanna jak2v617fvariantallelefrequencynondrivermutationssinglenucleotidevariantsandpolycythemiaveraoutcome
AT janowskimichał jak2v617fvariantallelefrequencynondrivermutationssinglenucleotidevariantsandpolycythemiaveraoutcome
AT wieckowskabarbara jak2v617fvariantallelefrequencynondrivermutationssinglenucleotidevariantsandpolycythemiaveraoutcome
AT paczkowskaedyta jak2v617fvariantallelefrequencynondrivermutationssinglenucleotidevariantsandpolycythemiaveraoutcome
AT lewandowskikrzysztof jak2v617fvariantallelefrequencynondrivermutationssinglenucleotidevariantsandpolycythemiaveraoutcome